CN105412354A - 黑枸杞护眼棒棒糖 - Google Patents
黑枸杞护眼棒棒糖 Download PDFInfo
- Publication number
- CN105412354A CN105412354A CN201510856781.9A CN201510856781A CN105412354A CN 105412354 A CN105412354 A CN 105412354A CN 201510856781 A CN201510856781 A CN 201510856781A CN 105412354 A CN105412354 A CN 105412354A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- lycium ruthenicum
- kilogram
- ruthenicum murr
- nourishing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000169546 Lycium ruthenicum Species 0.000 title claims abstract description 33
- 235000011475 lollipops Nutrition 0.000 title claims abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 72
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 65
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 34
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 34
- 239000011718 vitamin C Substances 0.000 claims abstract description 34
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 32
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 32
- 239000011709 vitamin E Substances 0.000 claims abstract description 32
- 229940046009 vitamin E Drugs 0.000 claims abstract description 32
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 24
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 24
- 239000011648 beta-carotene Substances 0.000 claims abstract description 24
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 24
- 229960002747 betacarotene Drugs 0.000 claims abstract description 24
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 24
- 239000011575 calcium Substances 0.000 claims abstract description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 16
- 235000001465 calcium Nutrition 0.000 claims abstract description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 14
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 11
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 11
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 11
- 235000021014 blueberries Nutrition 0.000 claims abstract description 11
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 9
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 9
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 9
- 239000011425 bamboo Substances 0.000 claims abstract description 9
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 8
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 8
- 239000011710 vitamin D Substances 0.000 claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 8
- 229940046008 vitamin d Drugs 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract 2
- 229930003270 Vitamin B Natural products 0.000 claims description 26
- 235000019156 vitamin B Nutrition 0.000 claims description 26
- 239000011720 vitamin B Substances 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 19
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 17
- 239000004212 Cryptoxanthin Substances 0.000 claims description 17
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 17
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 17
- 235000019244 cryptoxanthin Nutrition 0.000 claims description 17
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 11
- -1 VitAVitE Natural products 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 4
- 238000007493 shaping process Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 38
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 34
- 230000004438 eyesight Effects 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 31
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 30
- 235000019155 vitamin A Nutrition 0.000 abstract description 30
- 239000011719 vitamin A Substances 0.000 abstract description 30
- 229940045997 vitamin a Drugs 0.000 abstract description 30
- 230000006870 function Effects 0.000 abstract description 21
- 208000001491 myopia Diseases 0.000 abstract description 19
- 230000004379 myopia Effects 0.000 abstract description 18
- 230000006378 damage Effects 0.000 abstract description 14
- 208000003464 asthenopia Diseases 0.000 abstract description 13
- 210000004185 liver Anatomy 0.000 abstract description 13
- 208000002177 Cataract Diseases 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 208000002780 macular degeneration Diseases 0.000 abstract description 12
- 230000036039 immunity Effects 0.000 abstract description 11
- 201000009487 Amblyopia Diseases 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 230000003405 preventing effect Effects 0.000 abstract description 7
- 230000004436 pseudomyopia Effects 0.000 abstract description 7
- 235000009508 confectionery Nutrition 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 201000010041 presbyopia Diseases 0.000 abstract description 6
- 208000010412 Glaucoma Diseases 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 230000004304 visual acuity Effects 0.000 abstract description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract description 4
- 229960002477 riboflavin Drugs 0.000 abstract description 4
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 229960003495 thiamine Drugs 0.000 abstract description 4
- 229930003451 Vitamin B1 Natural products 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 208000029257 vision disease Diseases 0.000 abstract description 3
- 235000010374 vitamin B1 Nutrition 0.000 abstract description 3
- 239000011691 vitamin B1 Substances 0.000 abstract description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 abstract description 2
- 229930003471 Vitamin B2 Natural products 0.000 abstract description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 abstract description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 abstract description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 abstract description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract description 2
- 235000019164 vitamin B2 Nutrition 0.000 abstract description 2
- 239000011716 vitamin B2 Substances 0.000 abstract description 2
- 235000010930 zeaxanthin Nutrition 0.000 abstract description 2
- 239000001775 zeaxanthin Substances 0.000 abstract description 2
- 229940043269 zeaxanthin Drugs 0.000 abstract description 2
- 206010047571 Visual impairment Diseases 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 abstract 1
- 235000018927 edible plant Nutrition 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000009740 moulding (composite fabrication) Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000005496 tempering Methods 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 26
- 238000011160 research Methods 0.000 description 20
- 210000001525 retina Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000003064 anti-oxidating effect Effects 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 235000013339 cereals Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000004330 Rhodopsin Human genes 0.000 description 8
- 108090000820 Rhodopsin Proteins 0.000 description 8
- 230000035790 physiological processes and functions Effects 0.000 description 8
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 7
- 241001330002 Bambuseae Species 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 7
- 229920002414 procyanidin Polymers 0.000 description 7
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 6
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 208000035719 Maculopathy Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000001654 beetroot red Substances 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 210000000695 crystalline len Anatomy 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011604 retinal Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 5
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 4
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000001140 Night Blindness Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000012677 beetroot red Nutrition 0.000 description 4
- 235000002185 betanin Nutrition 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 150000001747 carotenoids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 235000020945 retinal Nutrition 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 230000003867 tiredness Effects 0.000 description 4
- 208000016255 tiredness Diseases 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 229940013640 flavin mononucleotide Drugs 0.000 description 3
- 239000011768 flavin mononucleotide Substances 0.000 description 3
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000010175 Opsin Human genes 0.000 description 2
- 108050001704 Opsin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004377 improving vision Effects 0.000 description 2
- 108010016980 iodopsin Proteins 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000002189 macula lutea Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000008558 metabolic pathway by substance Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000004515 progressive myopia Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000005494 xerophthalmia Diseases 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- PMTBZAVERRPRHU-YGVNLFKFSA-N CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C.CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C Chemical compound CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C.CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C PMTBZAVERRPRHU-YGVNLFKFSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000167686 Reichardia Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 230000004402 high myopia Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000008216 juvenile development Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000004423 myopia development Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 201000008525 senile cataract Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 239000011723 β-tocotrienol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 239000011722 γ-tocotrienol Substances 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
- A23G3/56—Products with edible or inedible supports, e.g. lollipops
- A23G3/563—Products with edible or inedible supports, e.g. lollipops products with an inedible support, e.g. a stick
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
黑枸杞护眼棒棒糖属于功能性糖果。尤以青藏高原天然无污染优质药食两用植物黑枸杞萃取物(蓝莓)、玉米黄质、β-胡萝卜素、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、钙等原料制成的产品。该产品具有补肾益精、养肝明目、健脾养胃、养血等功效,具有调节免疫力、防治近视、假性近视、治疗营养性弱视、防止假近视向真近视发展、消除眼睛疲劳、视力障碍、青光眼、老花眼、白内障、老年黄斑变性、抗氧化、防止糖尿病对视力的伤害有特殊的作用,该产品制作工艺:化糖、熬糖膏、调合搅拌、成型、插小竹棒、检验包装。
Description
一、技术领域:本发明属于功能性糖果,尤以青藏高原天然无污染优质药食两用植物黑枸杞萃取物(蓝莓)、玉米黄质、β-胡萝卜素、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、钙等原料,采取现代先进工艺加工而成的功能性糖果。
二、背景技术:该发明以黑枸杞萃取物(蓝莓)、玉米黄质、β-胡萝卜素、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、钙等原料制成的功能性糖果。该产品具有补肾益精、养肝明目、健脾养胃、养血等功效,具有调节免疫力、抗氧化、防治近视、假性近视、治疗营养性弱视、防止假近视向真近视发展、消除眼睛疲劳、视力障碍、青光眼、老花眼、白内障、老年黄斑变性,防止糖尿病对视力的伤害有特殊的作用。目前市场上还没有该产品出现,创新研制该产品,尤其给儿童、青少年改善视力等眼疾提供一种新产品,本产品为功能性糖果,属纯天然萃取物,纯度高、吸收好、生物活性强、味道纯正、无异味、无毒副作用、服用方便、效果明显。
三、发明内容:保护视力、珍爱生命。随着我国科学技术和经济的快速发展,工作和学习压力加大及不良的生活习惯,造成少年儿童长时间近距离用眼不当和饮食结构不合理等因素,加之电子游戏机、计算机普及与网络产业的发展,长时间玩游戏、上网、看电视等加剧了对儿童青少年视力的影响。使我国的儿童青少年近视人数正在逐年上升,并呈现出小龄化的趋势。据权威部门统计,目前我国有近视患者约3亿人,弱视1000多万,学生近视发病率为60%,居世界第一位。可见近视和弱视是一个相当严重的儿童视力健康问题,甚至关系到他们一生的幸福。因而,对儿童青少年的近视和弱视应该也必须积极有效地进行预防和治疗,并且从少儿、小学生抓起。因此,创新研发该产品对防治儿童青少年近视、弱视、消除眼疲劳等眼疾具有重要的意义。
四、原料配方:白砂糖20-30千克,葡萄糖10-15千克,饴糖15-20千克、黑枸杞萃取物(蓝莓)1-1.5千克、玉米黄质20-60千克、β-胡萝卜素10-30克、维生素A1-2克、维生素E60-80克、维生素D2-3克、维生素C0.8-1.2千克、维生素B10.5-3克、维生素B21-4克、钙1.5-2.0千克为原料。
五、技术方案:
(一)黑枸杞萃取物:(Lyciambarbarnmextraat),黑枸杞是生长在青藏高原绿色生态环境,纯天然珍品药食两用植物黑枸杞干燥果实。黑枸杞是一种稀有珍贵的原生态高端滋补品。黑枸杞为茄科植物枸杞成熟果实。性平,味甘。归肝、肾经。具有滋补肝肾、益精明目、润肺的功效。用于虚劳精亏、腰膝酸痛、眩晕耳鸣、内热消渴、血虚萎黄、提高视力、目昏不明等。现代医学研究认为,黑枸杞具有增强免疫力、抗疲劳、降血压、降血脂、降血糖、保护肝脏、减肥、抗衰老、抗癌等功能。
化学成分:黑枸杞含多糖、氨基酸、甜菜碱、胡萝卜素、维生素B、维生素C、烟酸等多种维生素以及锰、铬、锌、铜、镁、钙、锗、钴等微量元素。而且还有丰富的天然原花青素,其中原花青素含量是蓝莓含量的数倍,是迄今为止发现原花青素含量最高的天然野生植物。
药理作用:1、增强免疫力:小鼠灌服水提取物或肌注醇提取物均能显著增强其网状内皮***对印度墨汁的吞噬能力。水提取物或枸杞多糖均能促进小鼠腹腔巨噬细胞吞噬功能和血清中溶菌酶活性。给正常或老年小鼠灌服或腹枸杞多糖,能显著增强腹腔巨噬细胞c3b和Fc的受体数和活力,可使老年小鼠抑制性T细胞调节抗体功能恢复到成年小鼠的水平。黑枸杞多糖纯品比粗品具有更显著的免疫应答效应,各项免疫指标(包括非特异性免疫的免疫器官质量、巨噬细胞吞噬作用、特异性体液免疫的血清溶血素,特异性细胞免疫中的退发型***反应、淋巴细胞转化率、E玫瑰花结形成等)均有显著的差异。
2、保护肝脏、抗脂肪肝:黑枸杞提取物对保护肝脏和抗脂肪肝具有一定的作用。现代医学研究发现,黑枸杞中含有一种有效成分-甜菜碱,它对治疗肝脏疾病很有效。实验表明,甜菜碱有抑制脂肪在肝细胞内沉积,促进肝细胞再生的作用。另外,黑枸杞的中甜菜碱能防止肝脏内过多的脂肪贮存,有防脂肪肝的作用,据报道,长期经大鼠饲喂水提取物或甜菜碱饲料对ccl4引起的肝损害有保护作用,能明显降低转氨酶及肝中脂质的变化,可抑制肝中脂质沉积及促进肝细胞新生,对肝脏脂质过氧化损伤有明显的保护作用。
3、提高视力、消除眼睛疲劳:黑枸杞含有丰富的原花青素,具有较强的抗氧化功能,可有效减轻自由基对眼睛晶状体的损害,能保护眼睛细胞及视网膜,促进视紫红质细胞再生,提高视力敏锐度,加快黑暗中视力适应能力及闪光后的视力恢复的速度,促进眼部血液循环;缓解眼睛疲劳。对近视、弱视、白内障、畏光症、视网膜色素变性患者具有很好的防治作用。有人对75例因长期在显示屏前工作的眼睛疲劳患者,每天给予适量的原花青素,2个月后其相应敏感性和客观症状均有显著改善。给200名近视性视网膜非炎性患者服用2个月,其结果受试者视力明显提高。另据报道,黑枸杞具有养肝明目,提高视力的作用。医学临床报告显示,原花青素可以促进视网膜细胞中的视紫红质的再生成;可防治重度近视及视网膜剥离,并提高视力。据法国报道,研究人员证明,原花青素能明显改善眼睛疲劳的自觉症状。对电脑程序工作人员、办公人员和学生眼疲劳检定有明显的效果。美国报道,美国将花青素列为小学生有保护眼睛的作用,防止近视加深以及视网膜脱落等疾病的发生。尤其是电脑前工作的人员,长时间看电视、玩游戏以及视力衰退的人。
4、防治老年黄斑变性:黑枸杞对慢性肝病、中心性视网膜炎、视神经萎缩等眼疾有明显的防治作用。有助于降低老年黄斑变性的作用。老年黄斑变性是65岁以上患者丧失视力最主要的原因。黄斑主要是由玉米黄质组成,这种物质有助于抗氧化,并吸收容易损害眼睛细胞和组织的蓝光。研究发现,黑枸杞提取物可降低老年人患退行性黄斑变性的几率。参与临床研究的27名男女,其中14人连续28天服用黑枸杞,其余人服用水,研究人员在29天为两组人数空腹抽血,发现连续28天服用黑枸杞的一组血液中的玉米黄质较实验前增加了2.5倍,而对照组却没有增加。
5、防治老花眼:黑枸杞提取物具有补肝明目抗氧化的功效。能减轻自由基对眼睛晶状体的损害,保护眼睛细胞和视网膜,防治老花眼。
(二)玉米黄质(Zeaxanthin):它是广泛存在于禾科植物黄玉米、深绿色蔬菜、花卉和水果中的一种天然类胡萝卜素。是构成玉米、蔬菜、水果、花卉等植物色素的重要成分。共有8种异构体,以全反式为主,约占80%以上,玉米黄质等同属叶黄素类。类胡萝卜素是国际公认的具有抗病生理功能的天然物质。科学研究证明,玉米黄质除了对视力有保护作用外,还具有防治近视、白内障、老年退行性黄斑病变,增强免疫力、防治心血管疾病、抗氧化、预防动脉硬化,特别对预防癌症,延缓癌症恶化具有重要的作用。
生理功能:1、抗氧化:叶黄素其主要功能使单线态氧的有效淬灭剂,能清除羟基自由基,是脂质过氧化反应的断裂抗氧化剂,对人体疾病的预防发挥重要的作用。
2、保护视力:玉米黄质是眼睛视网膜和晶状体的唯一被发现的类胡萝卜素,是构成眼睛视网膜黄斑区域的主要色素。晶状体和视网膜黄斑区中所含的玉米黄质能将太阳中蓝色光过滤,掉以防止蓝色光对眼睛的伤害,因为蓝色光进入眼睛会产生大量的自由基,使人出现白内障,或使黄斑区退化变性,所以人体一旦缺乏玉米黄质,就会出现老年性视网膜黄斑病变、白内障、老花眼、假性近视、弱视、视疲劳等症状。研究发现,玉米黄质能淬灭单线态氧,抑制自由基的生成,对细胞中多不饱和脂肪酸及氧化起预防保护作用。因此具有保护视力的作用。
(三)β-胡萝卜素(β-Carotene),是存在于胡萝卜、红薯,海藻等天然植物的一种类胡萝卜素混合体。胡萝卜素有两种形式存在,即顺式和反式,而顺式具有更高的生物活性功能。β-胡萝卜素是一种脂溶性化合物,在人体内可转化为维生素A,是一种很强的抗氧化剂。据研究证实,β-胡萝卜素具有清除自由基,抗突变,保护心血管,保护视力,防癌抗癌,延缓衰老,美容养颜等功能。
生理功效:1、抗突变,β-胡萝卜素能保护和修复细胞微粒体膜的完整,以阻止超氧自由基的产生和破坏,避免脱氧核糖核酸(DNA)双键损伤,阻止遗传物质改变的诱发作用。
2、抗氧化:国内外大量研究证实,机体内的氧自由基不但会损害正常的细胞,还会引起细胞的畸变而形成癌症,而β-胡萝卡素是自由基最强的“克星”。β-胡萝卜素具有猝灭氧自由基,结合性氧自由基,形成非自由基化合物的能力。β-胡萝卡素和细胞膜双分子层的脂肪酸结合,以终止脂质过氧化反应。
3、增强免疫力:机体的免疫***由免疫器官和免疫细胞与免疫分子组成。β-胡萝卜素可促进吞筮细胞,淋巴细胞,多种免疫细胞的功能,促进细胞因子的释放,诱发能杀死肿瘤细胞的特异效应细胞以及免疫细胞间信息,传递必需因子的分泌,而β-胡萝卜素能提高宿主细胞的免疫功能,延缓细胞和机体衰老,减少疾病的发生。
4、保护DNA:β-胡萝卜素能防止DNA发生损伤,并有促进修复损伤的能力。小鼠淋巴细胞DNA链断裂后,在细胞培养液中加入β-胡萝卜素,经培养后DNA断裂链又重新连接上。补充β-胡萝卜素的受使者其淋巴细胞的微核细胞微核率显著低予安慰组的对照者。并且在补充β-胡萝卜素的前后均发现淋巴细胞微核率与血浆中β-胡萝卜素的浓度之间存在明显的负相关。
5、提高视力:胡萝卜素具有明显提高视力的功效。研究发现,β-胡萝卜素有助于提高视力,防止阳光对视网膜的损害。人体内所吸收的β-胡萝卜素差不多一半被转化为有助于视力的视紫红质,对于提高视力具有重要的作用。另据报道,β-胡萝卜素还能保护视力。动物实验证实,眼睛视力取决于眼睛的黄斑,如果没有足够的β-胡萝卜素,这些部位就会发生退行性病变,视力会逐渐减退,甚至会发生夜盲症,而β-胡萝卜素具有防止老年退行性黄斑病变,起到保护视力的作用。
(四)维生素A(VitA),又名视黄醇。是由20个碳和40个碳原子构成的不饱一元醇。包括维生素A(视黄醇)、维生素A2(视黄醛)和维生素A3(视黄酸),它们都具有天然维生素A活性的化合物。维生素A有两种,一种视黄醇是最初的维生素A形态,只存在于动物性食物中,另一种是β-胡萝卜素,是维生素A的前体,吸收后在人体内转变为视黄醇,它主要存在于一些植物性食物中,具有维生素A同样的生理作用。维生素A属脂溶性维生素。
维生素A是一组为视觉、生长、组织分化与增殖,生殖及免疫***完整所必需的化学物质。
生理功能:1、参与能量转换:研究表明,当体内维生素A摄入不足时,就有可能影响机体能量的正常代谢,使之过剩,从而转化为脂肪在体内储存,以产生肥胖,大量的研究结果证明,现实生活中我国大部分妇女、儿童摄取的能量,已基本上达到了膳食供应标准,但微量元素摄入普遍不足,不能满足机体主要生理需求,以致发生肥胖。
2、提高免疫力:医学研究表明,维生素A是维持上皮组织正常机能的必须物质,可以促进呼吸道等上皮细胞的分化和修复,保证粘膜的完整性,从而抵抗病毒的入侵,维生素A还有抗感染的功能,加锌能够帮助阻止病毒进入人体,使呼吸道免受感染,维生素A和锌协同作用可以改善维生素A的吸收和运转。进一步研究表明,血清维生素A与外周T细胞百分数和淋巴细胞转化率之间呈现着正相关。细胞培养显示,生理浓度的维生素A对淋巴细胞抗体的生成有明显的促进作用。维生素A可明显增加大鼠的胸腺重量、肺巨噬细胞数量并增强其吞噬功能,并且使免疫***的调节者。
3、维持粘膜、上皮组织的正常生长与分化:上皮组织遍及全身、呼吸、消化道、泌尿***、性腺以及其它腺体的上皮组织,正常的分化都需要的维生素A的参与。维生素A对上皮细胞的正常形成,发育及维持具有十分重要的作用。缺乏时上皮组织萎缩、干燥、增殖与角化,引起皮肤干燥、毛囊角化、毛发脱落、对眼睛可以引起干眼病、甚至失明。
4、维持正常视觉功能和防治近视:眼睛的光感受器是视网膜中的杆状细胞和锥细胞,这两种细胞都存在着光感色素,即感弱光的视紫红质和感光的视紫蓝质。视紫红质与视紫蓝质都是由视蛋白与视黄醛所构成,视紫红质经光照射后,II顺视黄醛异构成反视黄醛,并与视蛋白分离而失色,此过程称“漂白”。若进入暗处,则因对弱光不敏感的视紫红质消失,故不能见物。维生素A具有维持正常的视觉功能,直接参与视神经的代谢和内视紫红质的形成,对视网膜功能有重要的作用,对保护视力、防治近视也有一定的作用。此外,维生素A还可防止夜盲症、视力衰退、治疗各种眼疾,促进眼内感光色素的形成。维生素A缺乏症状为暗适应能力下降,严重者可导致夜盲,即在暗光下无法看清物质。由于角膜,结膜上皮组织,泪腺等退行病变,致角膜干燥,发炎、溃疡、角质化等一系列病变。严重缺乏维生素A,在结膜出现色状银灰色斑点、角膜严重损伤可导致不可逆转的失明。此外,维生素A还有助于对多种眼疾病(如眼球干燥与结膜炎)等的治疗。
5、抗视疲劳:长期在电脑前工作、看电视、玩游戏的人常会感到眼睛疲劳、干涩。科学研究指出,维生素A对视力能够起到有效的保护作用,可调试眼睛适应外界光线强弱的能力,以降低夜盲和视力减退的发生,维持正常的视觉反应、预防眼疲劳。
另外,维生素A还有促进儿童骨骼生长发育、抗呼吸道感染、祛除老年斑、美容等功效。
(五)维生素E(VItE)又名生育酚。即E、β、γ与δ生育粉,α、β、γ与δ-三烯生育酚8种同族***为维生素E。其中α一生育酚的生物活性最强。维生素E属于脂溶性维生素。
生理功能:1、抗氧化:维生素E是一种很强的抗氧化剂,在保护细胞膜免受自由基的损害。脑细胞含有大量的不饱和脂肪酸,维生素E能防止不饱和脂肪酸被氧化,从而保护大脑细胞的正常代谢与活动,防止大脑氧化衰退。维生素E还可保护神经***,骨骼肌、视网膜免受氧化损害,人体神经***的正常发育和视网膜,需要充足的维生素E。神经***在产生神经递质过程中伴有大量的自由基产生,因此维生素E在防止线粒体和神经***的触突膜免受自由基损害方面是必需的。
2、防治糖尿病并发症:天然维生素E是一种强抗氧化剂,并能参与机体多方而的代谢过程。近年来,也用于医治糖尿病慢性并发症,尤其是心血管并发症,而心血管并发症约占糖尿病人死亡原因的70%左右。
3、防治冠心病:维生素E可预防心脏冠状动脉硬化和血栓的形成,从而避免引起冠心病或心肌硬死。维生素E具有抗氧化作用,能防止过氧化脂质在血管壁沉积,预防动脉硬化的发生。维生素E可降低血液黏稠度,使血液流通顺畅,从而增加心脏的供氧,减轻心脏负担。
4、维生素E防治白内障、黄斑病变:维生素E具有抗氧化作用,可以抑制晶状体内的过氧化脂质反应,使末梢血管扩张,改善血液循环,能促进眼病变恢复。研究认为,血液中的维生素E含量低时会促使白内障的产生,因为维生素E降低时会增加氧化反应,易使晶状体的蛋白质凝集变为混浊。据美国塔夫斯大学人类营养研究中心的研究表明,通过服用维生素E白内障和老年退行性黄斑病变是可以预防的。研究结果显示,在饮食中摄入维生素E的老年人,极少患上白内障和老年黄斑病变。加拿大的一项研究发现,服用维生素E的老年人比不服用患者白内障可减少50%。进一步研究发现,维生素E降低时会增加氧化反应,易使晶状体的蛋白凝集变为混浊。
5、抗紫外线:维生素E具有较强的抗紫外线功效。科学研究证实,维生素E能使人体具备更强的抗紫外线能力,即维生素E它能够强化其它防紫外线的物质的功能,并加强眼睛更好抵御辐射对视力的伤害。实验证明,在抗紫外线能力上,未服维生素E要比服维生素E的人低29%。因此,维生素E能够增强抗紫外线能力,防止眼睛被紫外线伤害。
(六)维生素C(VitC)又名抗坏血酸。是广泛存在于水果和蔬菜中的天然物质。维生素C是一种简单六碳化合物,自然界中有两种存在形式,即还原型抗坏血酸和氧化型脱氢抗坏血酸,两者都有生理活性,均可被机体利用。
生理功能:1、参与生物合成,维生素C在体内消化过程中作为底物的酶和辅酶因子参与多种重要的生物合成过程,包括胶原蛋白,肉碱其它神经递质和肽激素合成及酪氨酸代谢等。有些酶需要维生素C才能保持高度的活性。
2、保护神经细胞,研究发现,眼睛中的神经细胞需要依靠维生素C来发挥正常的功能。美国研究人员发现,视网膜细胞内部和外部需要在相应较高的浓度的维生素C才能发挥正常的功能。由于视网膜是中枢神经***的一部分,因此,维生素C很可能在大脑中起到了意想不到的重要作用。
大脑中存在一种叫做GABA类型的受体,其作用使帮助调节大脑细胞间的快速通信。研究人员发现,在去掉维生素C后,视网膜细胞中这些受体,就不能发挥正常功能。由于视网膜细胞与大脑细胞非常接近,因此大脑中的其他部位的GABA受体要想正常发挥作用也需要维生素C。维生素C对这些受体和细胞有保护作用。这一发现对青光眼有重要的意义。因为青光眼与视网膜和大脑中的神经细胞过渡活跃有关,原因是GABA受体功能出现异常。因此,维生素C对视网膜产生神经保护作用。
3、明亮眼睛:眼睛中的维生素C含量要比血液中约高数倍,随着年龄的增长,营养吸收代谢功能逐渐减退,眼睛中的维生素C含量下降,久而久之,容易引起晶状体营养不良、变性,因此,维生素C可明亮眼睛。
4、防止视网膜出血:人的机体缺少维生素C可使毛细血管通透性增加,血管硬化,眼敛皮水肿,容易引发眼敛、前房、玻璃体、视网膜出血。维生素C可降低毛细血管通透性,提高眼部毛细血管弹性。因而防止视网膜出血的发生。
5、消除疲劳:维生素C参与体内各种营养的氧化还原过程,对蛋白质的代谢有很大的影响,在重体力劳动时补充维生素C,可以提高肌肉的耐力,加速体力恢复。
6、提高免疫力、抗感冒:维生素C能促进***和淋巴液分泌,使机体产生干扰素和抗毒素,从而起到免疫和抗病毒作用,提高对机体组织的控制能力,有助于合成能调节淋巴细胞的***素。美国专家研究表明,每天1克左右维生素C可使感冒下降45%,病程缩短60%。维生素C可沟通呼吸器官和促进血液循环,抗呼吸道感染,增强机体需要的氧化,减少感冒发生。维生素C除了上述功能外,还具有维护皮肤健康、抗衰老等多种功能。
(七)维生素B1(VitB1),又名硫胺素。抗脚气病维生素和抗神经炎素,是人类发现最早的维生素之一。
维生素B1,在体内广泛分布于各个组织中,骨骼肌、心、肝和肾脏组织中含量最高,肌肉中含量占总量的1/2。
生理功能:1、参与物质和能量代谢;维生素B,与糖代谢密切相关。维生素B1以羟化酶转羟乙醛酶的辅酶参与糖代谢中的两个反应,a一丙酮酸氧化脱羟作用,是丙酮酸转变为乙酰COA与酮戌二酸转变为琥珀酸SOA,是磷酸戌途转酮基酶反应。缺乏时可使丙酮酸合成乙酰酶A减少,从而抑制脑神经内Ach的合成。这两个反应是三大营养分解代谢的关键环节,又是它们合成代谢的联结点,另据报道,维生素B1能促进体内糖代谢,使糖代谢中间产物丙酮酸彻底氧化,促进能量代谢。
2、防治近视:维生素B1是维持并参与神经(包括视神经)细胞功能和代谢的重要物质。如果缺乏不足,会使眼睛干涩,甚至使神经产生炎症等,表现为眼睛干燥、视力下降、目瞳散大、对光反应迟钝、眼动时有牵拉痛、眼眶深部有压痛感等。这是因为维生素B1主要生理作用促进细胞的新陈代谢的过程,特别与神经的传导功能有关。维生素B1能延缓上述症状。此外,维生素B1缺乏会使睫状肌的调节功能减退,容易发生疲劳,促进近视眼的发生。所以维生素B1对预防近视眼有重要的意义。
3、消除疲劳:维生素B1是构成脱羧酶的重要物质:它参与糖的代谢,促进乙酰胆碱合成,并防止分解,维持肠胃的正常蠕动和消化腺的分泌;促进和维持碳水化合物的代谢。如果维生素B1缺乏和不足,是人感到乏力,因此,常补充维生素B1可以消除疲劳。
(八)、维生素B2(VItB2)又名核黄素,它是一种D一核黄醇的生物。食物中的核黄素以辅酶黄素单核苷酸(FMN),黄素嘌腺吟二核苷酸(FA0)形式存在。维生素B2是一种水溶性维生素。
生理功能:1、参与能量和物质代谢:维生素B2在体内是以辅酶形式参与糖、脂肪、蛋白质的代谢,它还是脂肪转化为能量不可缺少的基础物质。维生素B2在生物氧化过程中,作为递氢体,而具有递氢作用,从而对物质代谢过程发生影响。
2、防治眼疾:维生素B2对防治眼疾具有重要的作用。如果维生素B2缺乏,视网膜功能下降,眼球结膜充血,角膜周围血管增生,角膜与结膜相连处有时发生水泡,严重时角膜下部有溃疡,有敛缘炎、疲劳、视物模糊、流泪等。也有发现儿童近视、弱视、视网膜病和老年白内障与维生素B2缺乏有关。
3、消除疲劳:维生素B2是构成人体多种呼吸酶的辅酶,是蛋白质、碳水化合物、脂肪代谢和能量利用组成的必需物质。维生素B2缺乏或不足,肌肉运动无力、耐力下降、也容易产生疲劳。
(九)、钙(Ca),钙是多功能营养素。是人体构成的主要成分,约占人体的2%。钙不仅是构成机体完整性不可缺少的组成成分,而且在生长发育和生理生化过程中对维持生命起着重要的作用。
生理功能:1、防治近视:眼球的转动需要肌肉的拉动,而钙与肌肉的灵活性关系十分密切。如果膳食长期缺球转动不灵活,眼肌调节能力和恢复能力差,甚至发生眼轴拉长而导致近视度加深。青少年发育高峰期,如果钙摄入不足,可以使在发育中的眼球壁巩膜的弹性降低,眼球内的液体压力升高,致使眼球的前后经拉长而导致近视。
缺钙还容易出现视疲劳和注意力分散。
综上所述:本产品补肾益精、养肝明目、健脾养胃、益血等功效。具有防治近视、假近视、视力障碍、治疗营养性弱视、消除眼睛疲劳、防止假近视向真近视发展、防治青光眼、老花眼、白内障、老年黄斑变性、抗氧化、防止糖尿病对视力的伤害、调节免疫力等有特殊的作用。
六、制作工艺:
1、化糖:先将配方中种糖分白砂糖、葡萄糖、饴糖混合加入15-30%的热水充分溶化。
2、熬糖膏:将溶化后的糖液加温130℃-160℃进行熬糖膏,当糖膏熬至水分含量为3-5%出锅。
3、调合与搅拌:将出锅后的糖膏加入配方中剩余原料黑枸杞萃取物(蓝莓)、玉米黄质、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、钙调合,充分搅拌均匀。
4、成型:是将调合搅拌均匀的原料糖膏送入成型机制作成为糖粒。
5、插小竹棒:将成型后的糖粒插上小竹棒。
6、检验包装:将***小竹棒的糖粒检验合格,包装为成品。
化糖工序是将配中的砂糖、葡萄糖和饴糖混合加入热水中充分溶化的过程。熬糖膏工序是将溶化后的糖液在设计温度下熬至成为透明状态糖膏的过程。调合搅拌工序是将配方中剩余的原料黑枸杞萃取物(蓝莓)、玉米黄质、维生素A、维生素E、维生素D、维生素C、维生素BI、维生素B2、钙和前工序制得的糖膏混合,充分搅拌均匀的过程。成型工序是将调合搅拌均匀的糖膏送入成型机制作成为糖粒的过程。插小竹棒工序是成型后的糖粒***小竹棒的过程。检验包装工序是将***小竹棒的糖粒检验合格,包装为成品的过程。
七、质量标准:
1、理化指标:
黑枸杞萃取物 | g/100g | 1.5 |
玉米黄质 | mg/100g | 60 |
β-胡萝卜素 | mg/100g | 30 |
维生素A | mg/100g | 0.1 |
维生素E | mg/100g | 70 |
维生素D | mg/100g | 0.2 |
维生素C | g/100g | 0.75 |
维生素B1 | mg/100g | 10 |
维生素B2 | mg/100g | 15 |
钙 | g/100g | 1.0 |
2、适应人群:适应于儿童青少年和电脑前工作人员以及各年龄段人群。
3、服用方法:每日服用1-3次,每次服用量10克
八、实施例:取白砂糖20-30千克,葡萄糖10-15千克,饴糖15-20千克、黑枸杞萃取物(蓝莓)1-1.5千克、玉米黄质20-60千克、β-胡萝卜素10-30克、维生素A1-2克、维生素E60-80克、维生素D2-3克、维生素C0.8-1.2千克、维生素B10.5-3克、维生素B21-4克、钙1.5-2.0千克为原料,先将白砂糖、葡萄糖、饴糖混合加入20-30%热水充分溶化,加热至130℃-160℃熬糖膏,当糖膏熬至水分含量为3-5%出锅,再将配方中剩余的原料黑枸杞萃取物(蓝莓)、玉米黄质、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、钙加入出锅的糖膏中调合,充分搅拌均匀,送入成型机制作成为糖粒,在糖粒上***小竹棒,检验合格,包装为成品。
Claims (1)
1.黑枸杞护眼棒棒糖制作工艺,其特征为:白砂糖20-30千克,葡萄糖10-15千克,饴糖15-20千克、黑枸杞萃取物(蓝莓)1-1.5千克、玉米黄质20-60千克、β-胡萝卜素10-30克、维生素A1-2克、维生素E60-80克、维生素D2-3克、维生素C0.8-1.2千克、维生素B10.5-3克、维生素B21-4克、钙1.5-2.0千克为原料,经过将白砂糖、葡萄糖、饴糖混合溶化20-30%的热水中,加温至130℃-160℃熬糖膏,当糖膏熬至水分含量为3-5%出锅,再将配方中剩余的黑枸杞萃取物(蓝莓)、玉米黄质、维生素A、维生素E、维生素D、维生素C、维生素B1、维生素B2、钙加入出锅后的糖膏中调合,充分搅拌均匀,送入成型机制作成为糖粒,在糖粒上***小竹棒,检验合格,包装为成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510856781.9A CN105412354A (zh) | 2015-12-01 | 2015-12-01 | 黑枸杞护眼棒棒糖 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510856781.9A CN105412354A (zh) | 2015-12-01 | 2015-12-01 | 黑枸杞护眼棒棒糖 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105412354A true CN105412354A (zh) | 2016-03-23 |
Family
ID=55491201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510856781.9A Pending CN105412354A (zh) | 2015-12-01 | 2015-12-01 | 黑枸杞护眼棒棒糖 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105412354A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107094974A (zh) * | 2017-07-06 | 2017-08-29 | 天津杞源堂生物工程有限公司 | 一种黑枸杞保健糖果及其制备方法 |
CN110226751A (zh) * | 2019-07-10 | 2019-09-13 | 完美(广东)日用品有限公司 | 一种具有眼保护功效的组合物 |
CN112655971A (zh) * | 2020-12-21 | 2021-04-16 | 康洛信(广东)生物科技有限公司 | 一种缓解眼睛干涩疲劳的胶原蛋白肽组合物及其制备方法 |
CN114652776A (zh) * | 2017-04-03 | 2022-06-24 | 大江生医股份有限公司 | 一种包含植物萃取物的组合物及其促进睾固酮分泌的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN202354309U (zh) * | 2011-11-24 | 2012-08-01 | 福建省好邻居食品工业有限公司 | 一种可保护视力的棒棒糖 |
-
2015
- 2015-12-01 CN CN201510856781.9A patent/CN105412354A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN202354309U (zh) * | 2011-11-24 | 2012-08-01 | 福建省好邻居食品工业有限公司 | 一种可保护视力的棒棒糖 |
Non-Patent Citations (3)
Title |
---|
张忠盛等: "《糖果巧克力生产技术问答》", 31 August 2009, 中国轻工业出版社 * |
田建华等: "《怎么吃降血压降血脂》", 31 January 2014, 上海科学普及出版社 * |
郑建仙: "《功能性食品学》", 31 March 2006, 中国轻工业出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114652776A (zh) * | 2017-04-03 | 2022-06-24 | 大江生医股份有限公司 | 一种包含植物萃取物的组合物及其促进睾固酮分泌的用途 |
US11806317B2 (en) | 2017-04-03 | 2023-11-07 | Tci Co., Ltd. | Composition capable of promoting testosterone secretion and use thereof |
CN114652776B (zh) * | 2017-04-03 | 2024-01-30 | 大江生医股份有限公司 | 一种包含植物萃取物的组合物及其促进睾固酮分泌的用途 |
CN107094974A (zh) * | 2017-07-06 | 2017-08-29 | 天津杞源堂生物工程有限公司 | 一种黑枸杞保健糖果及其制备方法 |
CN110226751A (zh) * | 2019-07-10 | 2019-09-13 | 完美(广东)日用品有限公司 | 一种具有眼保护功效的组合物 |
CN112655971A (zh) * | 2020-12-21 | 2021-04-16 | 康洛信(广东)生物科技有限公司 | 一种缓解眼睛干涩疲劳的胶原蛋白肽组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103431404A (zh) | 护视明眼胶囊 | |
EP2138055B2 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
CN106615178B (zh) | Dha藻油固体饮料 | |
CN104544052A (zh) | 黑枸杞护视明目含片 | |
CN103977157A (zh) | 黑枸杞明目的护眼茶 | |
CN108157568A (zh) | 一种缓解视疲劳的组合糖果及其制备方法和用途 | |
WO2005110375A1 (en) | Nutritional supplement for treatment of ocular diseases | |
CN103735733A (zh) | 一种含叶黄素酯的复方制剂及其制备方法 | |
CN109663122A (zh) | 一种为视网膜黄斑区提供营养、改善视力、预防眼病的组合物颗粒冲剂及其制备方法 | |
CN105412354A (zh) | 黑枸杞护眼棒棒糖 | |
CN105011154A (zh) | 一种缓解青少年视疲劳促进记忆力的组合物及其制备方法 | |
US20160151437A1 (en) | Nutritional supplements for improved vision and methods of treating the same | |
CN111802476A (zh) | 一种提高儿童睡眠质量的奶粉及其制备方法 | |
CN109619566A (zh) | 一种缓解视力疲劳的营养食品 | |
CN100574772C (zh) | 一种含叶黄素的软胶囊及其制备方法 | |
CN105011153A (zh) | 一种促进儿童眼脑发育缓解视疲劳的组合物及其制备方法 | |
CN101283806A (zh) | 一种含天然叶黄素的膳食补充剂及制备工艺 | |
CN108041609B (zh) | 一种具有缓解视疲劳、预防近视的食品组合物及其制备方法 | |
CN107712537A (zh) | 一种叶黄素酯固体饮料 | |
CN111202243A (zh) | 强化明目营养软胶囊特殊膳食食品及其制备方法 | |
CN105520137B (zh) | 一种具有缓解视疲劳和保护视力功能的保健食品 | |
CN1685888A (zh) | 康视明酸奶片 | |
CN106692187A (zh) | 一种用于改善明视持久度、保护眼睛健康的组合物 | |
CN111513110A (zh) | 含有叶黄素的蓝莓护眼饼干及其制备方法 | |
CN104921123A (zh) | 一种促进幼儿眼脑发育的组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination |